Clinical trials: Stem Cell Mobilization
Relapsed Multiple Myeloma
Non-interventional Study on Salvage Auto in Relapsed Myeloma
Multiple myeloma (MM) is an incurable disease that is characterized by the accumulation of clonal plasma cells in the bone marrow.
- Trial name
- IFM-2015-03 (NCT02439476)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005631
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
- Trial name
- NCT00948922
- Testing
- Bortezomib, Melphalan, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed…
- Trial name
- NCT00002789
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and…
- Trial name
- NCT01182675
- Testing
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia (AML)
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
During the pre-transplantation phase (following completion of consolidation chemotherapy), patients will begin to receive G-CSF at 10 mcg/kg twice daily; leukapheresis will also be given until a target goal for recipient body…
- Trial name
- NCT00363467
- Testing
- G-CSF, Leukapheresis, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Coronary Syndromes
Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes
This prospective study aimed to validate a new prognostic approach of endothelial progenitor cells associated biomarkers in patients with acute coronary syndromes .
- Trial name
- NCT02117037
- Testing
- blood sample
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Lymphoma
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00274794
- Testing
- filgrastim, rituximab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- The Cleveland Clinic
Normal PBPC Donors
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.
- Trial name
- NCT00115128
- Testing
- filgrastim
- Volunteers
- 309 people
- Sponsor
- Amgen
Sarcopenia, Stroke, Acute
Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients
The primary aim of the study is to assess the mobility dose in neurocritical care patients with ischemic stroke or intracranial hemorrhage and its effects on discharge disposition and patient outcomes.
- Conditions
- Sarcopenia, Stroke, Acute, Muscle Weakness, Critical Illness
- Trial name
- NCT03347656
- Where
- 3 sites in United States, Germany
- Volunteers
- 164 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cardiovascular Disease
Growth Hormone's Effect on Endothelial Progenitor Cells
To assess the effect of short-term low-dose growth hormone therapy on the mobilization of endothelial progenitor cells from the bone marrow within a group of healthy adults.
- Trial name
- NCT00397592
- Testing
- Growth Hormone
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Sickle Cell Disease Without Crisis
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
Sickle cell disease (SCD) is one of the most common genetic diseases in the world. In North America, an estimated 2600 babies are born with SCD each year1, and approximately 70,000 to 100,000 individuals of all ages are affected…
- Trial name
- NCT02989701
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Alessandra Biffi
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
The reason for doing this study is to see if cancer will respond to immune therapy after transplantation of blood stem cells (from the bone marrow) using a new kind of treatment regimen that is less toxic than that previously…
- Trial name
- NCT00005851
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Stable Coronary Artery Disease
Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents
The purpose of this study is to evaluate the extent of the mobilization of endothelial progenitor cells induced by low versus high dose atorvastatin after 4 weeks of treatment, in patients treated with anti-CD 34 antibodies…
- Trial name
- NCT00911339
- Testing
- Atorvastatin
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Myeloma
PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma
High-dose chemotherapy with autologous stem cell support is the current standard procedure in the first-line treatment in younger patients with myeloma fit for intensive treatment.
- Trial name
- PAV (NCT01220375)
- Testing
- Vinorelbine, G-CSF, & Plerixafor, Vinorelbine and Plerixafor, G-CSF and Plerixafor
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Leukemia, Myeloproliferative Disorders
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated…
- Conditions
- Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00075816
- Testing
- Allogeneic bone marrow transplantation, Peripheral blood stem cell transplantation
- Where
- 45 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- Medical College of Wisconsin
Low Back Pain
Myofascial Release and Joint Mobilization Therapy in Non-Specific Low Back Pain
Low back pain is a common condition affecting many individuals at some point in their lives. The prevalence of Non-specific low back pain (LBP) is between 4.2% and 19.6%, which is responsible for high treatment costs, sick leave…
- Trial name
- NCT04860726
- Testing
- Joint mobilization, Myofascial Release, Joint mobilization & Myofascial Release
- Where
- 2 sites in Pakistan
- Volunteers
- 84 people
- Sponsor
- Riphah International University
COPD, Cystic Fibrosis
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood of normal controls and patients awaiting lung…
- Conditions
- COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01916577
- Testing
- Plerixafor mobilization of autologous CD117 stem cells
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell…
- Trial name
- NCT07101445
- Testing
- Acetaminophen, Biospecimen Collection, Dexamethasone
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Lymphoma, Non-Hodgkin
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal…
- Trial name
- NCT00103610
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 32 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Genzyme, a Sanofi Company